인간 생식 기술 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, human reproductive technologies market size in 2026 is estimated at USD 33.46 billion, growing from 2025 value of USD 32.64 billion with 2031 projections showing USD 37.87 billion, growing at 2.51% CAGR over 2026-2031.

This report is Segmented by Reproductive Technology (Infertility Treatment and Contraceptives), Gender (Male and Female), End User (Fertility Clinics, Hospitals & Surgical Centers, and More), Product Mode (Drugs, Devices and Equipment), and Geography. The Market Sizes and Forecasts are Provided in Terms of Value (USD).

Global Human Reproductive Technologies Market Trends and Insights

Rising Prevalence of Infertility

One in six adults now experiences infertility at some stage, underscoring a public-health challenge that drives sustained demand for advanced reproductive care. In the United States, the share of married women under 50 who reported infertility rose to 8.7% in 2019, up from 6.7% in the earlier half of the decade . Several Asia-Pacific economies face even sharper pressures, with South Korea's total fertility rate plummeting to 0.8, the lowest worldwide. Environmental exposure, lifestyle changes, and postponement of childbearing compound biologic risk, pushing more couples toward assisted reproductive technology (ART). These factors collectively sustain the mid-single-digit growth segments within the broader human reproductive technologies market.

Continuous Technological Progress-ICSI & Pre-implantation Genetic Testing

AI-enhanced embryo selection now achieves up to 75% clinical pregnancy-prediction accuracy, improving over traditional morphology-only assessment . Robot-controlled intracytoplasmic sperm injection (ICSI) has demonstrated higher fertilization rates while allowing remote operation over distances exceeding 2,300 miles. Non-invasive pre-implantation genetic testing that analyzes cell-free DNA in spent culture media matches the concordance of biopsy-based methods, reducing embryo manipulation risk. Time-lapse imaging systems combined with deep learning allow continuous embryo monitoring without exposure changes, optimizing selection protocols. Such advances cut cycle numbers, raise success rates, and compress patient costs, reinforcing adoption across the human reproductive technologies market.

Limited Insurance Coverage for ART

Even as employer benefits expand, many patients still face out-of-pocket costs of USD 12,000-25,000 per IVF cycle in the United States, limiting uptake among middle-income households. In numerous low- and middle-income countries, ART fees can exceed 200% of GDP per capita, rendering services inaccessible for the vast majority. Insurance policies often cover diagnostics while excluding treatment, creating fragmented pathways that suppress the potential of the human reproductive technologies market. These reimbursement gaps slow volume growth, especially in price-sensitive emerging markets.

Other drivers and restraints analyzed in the detailed report include:

1. Delayed Family Planning & Higher Maternal Age
2. Growing Government Support & Reimbursement
3. Ethical & Religious Opposition

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Contraceptive solutions dominated revenue with a 58.02% stake in 2025, testifying to long-established demand across demographics. Oral pills remain the mainstay, yet long-acting reversible contraception gains share as next-generation intra-uterine systems introduce sustained-release mechanisms. In parallel, infertility treatments outpace overall human reproductive technologies market growth, registering a 3.02% CAGR projected through 2031. Broadening public funding, AI-guided embryo analytics, and reduced procedural complexity propel treatment cycles higher, especially in Asia-Pacific clinics. Combination drug-and-device protocols lower stimulation doses and shorten cycle lengths, broadening patient appeal.

R&D investment targets gamete quality enhancement, non-invasive genetic testing, and robotic micromanipulation-areas anticipated to lift success-rate benchmarks beyond today's 42% live-birth per cycle ceiling. As a result, integrated providers that offer both preventive and therapeutic services position themselves to capture rising cross-segment demand within the human reproductive technologies market.

The female segment commanded 85.05% of revenue in 2025, anchored by contraceptive prevalence and well-established fertility treatments. However, breakthrough male contraceptive pipelines promise to reshape share dynamics. A topical hormonal gel now in Phase III delivers 86% sperm suppression within 15 weeks, faster than historic injectables. Non-hormonal options such as selective retinoic acid receptor antagonists and hydrogel-based vas-occlusive implants advance through early trials, appealing to men seeking reversible methods without hormonal side effects.

Male infertility diagnostics also benefit from AI-assisted sperm-quality prediction, reducing laboratory workload while increasing predictive accuracy. These innovations explain the segment's forecast-leading 3.28% CAGR, illustrating how the human reproductive technology industry is broadening gender-inclusive care portfolios.

Complete Report Scope:

• By Reproductive Technology
  • Infertility Treatment
    • Drugs
      • Follitropin Alfa
      • Follitropin Beta
      • Menotropins
      • Others
    • Devices
      • Sperm Separation Devices
      • Sperm Analyzer Systems
      • Ovum Aspiration Pumps
      • Micromanipulator Systems
      • Others
  • Contraceptive
    • Drugs
      • Oral Contraceptives
      • Topical Contraceptives
      • Contraceptive Injectables
    • Devices
      • Condoms
      • IUD
      • Cervical Caps
      • Diaphragms
• By Gender
  • Male
  • Female
• By End User
  • Fertility Clinics
  • Hospitals & Surgical Centers
  • Homecare & OTC
  • Research Institutes
• By Product Mode
  • Drugs
  • Devices & Equipment
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 44.78% of 2025 revenue, benefiting from mature healthcare financing, broad employer fertility benefits, and early adoption of AI-driven clinical protocols. The region also enacts supportive federal policy, exemplified by the 2025 executive order extending IVF benefits to military and civil-service families. Yet growth is partially constrained by a projected shortfall of 5,170 reproductive endocrinologists by 2030, which intensifies competition for clinical talent and incentivizes tele-medicine and robotic solutions to balance supply gaps.

Asia-Pacific represents the fastest-growing geography with a 3.92% CAGR expected through 2031. Policy levers play a central role: China's exploration of national ART reimbursement could unlock millions of incremental treatment cycles per year. Japan's updated surgical codes for IVF and ICSI similarly expand coverage, while Singapore and Malaysia subsidize up to 75% of treatment costs to combat declining birth rates. Fertility tourism into regional hubs further boosts procedure volumes and encourages high-tech clinic build-outs.

Europe maintains steady, mid-single-digit growth as universal health systems shield patients from high out-of-pocket spend. The region also hosts leading research networks such as ESHRE, which disseminate best-practice standards adopted worldwide. Regulatory debate over embryo-testing ethics and cross-border surrogacy can lengthen approval timelines, yet clinical sophistication and high disposable income sustain procedure uptake.

Emerging economies in the Middle East, Africa, and South America still account for a modest slice of human reproductive technologies market size, but investment in private clinics and technology transfer partnerships is catalyzing double-digit local growth rates from a low base.

1. The Cooper Companies
2. Teva Pharmaceutical Industries
3. Abbvie
4. Ferring Pharmaceuticals
5. Merck
6. Genea
7. IVFtech ApS
8. Bayer
9. Pfizer
10. Organon
11. Vitrolife
12. Cook Group
13. Thermo Fisher Scientific
14. Boston IVF
15. Virtus Health Ltd.
16. Progyny Inc.
17. Reckitt Benckiser Group
18. Okamoto Industries Inc.
19. Perrigo Company
20. Care Fertility Group

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Prevalence Of Infertility
  • 4.2.2 Continuous Technological Progress-Icsi, Pre-Implantation Genetic Testing
  • 4.2.3 Delayed Family Planning & Higher Maternal Age
  • 4.2.4 Growing Government Support & Reimbursement
  • 4.2.5 Employer-Funded Fertility-Benefit Programs
  • 4.2.6 Ai-Powered Embryo & Gamete Analytics
• 4.3 Market Restraints
  • 4.3.1 Limited Insurance Coverage For Art
  • 4.3.2 Ethical & Religious Opposition
  • 4.3.3 Stringent Regulatory Pathways And Lengthy Approval Timelines
  • 4.3.4 Shortage Of Reproductive Endocrinologists
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Bargaining Power of Suppliers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts

• 5.1 By Reproductive Technology
  • 5.1.1 Infertility Treatment
    • 5.1.1.1 Drugs
      • 5.1.1.1.1 Follitropin Alfa
      • 5.1.1.1.2 Follitropin Beta
      • 5.1.1.1.3 Menotropins
      • 5.1.1.1.4 Others
    • 5.1.1.2 Devices
      • 5.1.1.2.1 Sperm Separation Devices
      • 5.1.1.2.2 Sperm Analyzer Systems
      • 5.1.1.2.3 Ovum Aspiration Pumps
      • 5.1.1.2.4 Micromanipulator Systems
      • 5.1.1.2.5 Others
  • 5.1.2 Contraceptive
    • 5.1.2.1 Drugs
      • 5.1.2.1.1 Oral Contraceptives
      • 5.1.2.1.2 Topical Contraceptives
      • 5.1.2.1.3 Contraceptive Injectables
    • 5.1.2.2 Devices
      • 5.1.2.2.1 Condoms
      • 5.1.2.2.2 IUD
      • 5.1.2.2.3 Cervical Caps
      • 5.1.2.2.4 Diaphragms
• 5.2 By Gender
  • 5.2.1 Male
  • 5.2.2 Female
• 5.3 By End User
  • 5.3.1 Fertility Clinics
  • 5.3.2 Hospitals & Surgical Centers
  • 5.3.3 Homecare & OTC
  • 5.3.4 Research Institutes
• 5.4 By Product Mode
  • 5.4.1 Drugs
  • 5.4.2 Devices & Equipment
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 CooperSurgical Inc.
  • 6.3.2 Teva Pharmaceutical Industries Ltd.
  • 6.3.3 AbbVie Inc.
  • 6.3.4 Ferring B.V.
  • 6.3.5 Merck KGaA
  • 6.3.6 Genea Limited
  • 6.3.7 IVFtech ApS
  • 6.3.8 Bayer AG
  • 6.3.9 Pfizer Inc.
  • 6.3.10 Organon & Co.
  • 6.3.11 Vitrolife AB
  • 6.3.12 Cook Medical LLC
  • 6.3.13 Thermo Fisher Scientific Inc.
  • 6.3.14 Boston IVF
  • 6.3.15 Virtus Health Ltd.
  • 6.3.16 Progyny Inc.
  • 6.3.17 Reckitt Benckiser Group plc
  • 6.3.18 Okamoto Industries Inc.
  • 6.3.19 Perrigo Company plc
  • 6.3.20 Care Fertility Group

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment